Apotex and Grünenthal have entered into a licensing agreement whereby Apotex will have the exclusive Canadian rights to Nebido® (testosterone undecanoate), a long-acting injectable therapy indicated for the treatment of male hypogonadism (testosterone deficiency).
Under the agreement, Searchlight Pharma, Apotex's branded medicine division, will pursue marketing authorization and will market and distribute the product in Canada upon regulatory approval. Grünenthal will receive an upfront payment, regulatory milestone payments, and a margin on the sales.
This agreement deepens the existing partnership between Apotex and Grünenthal and strengthens their shared commitment to expanding Canadian patients' access to important therapies.
"This marks an important step in Apotex's mission to broaden access to innovative medicines and advance our purpose as a Force for Health, says Mark Nawacki, President, Searchlight Pharma. "Nebido® addresses a recognized need in men's health and represents our first entry into testosterone therapy — opening a meaningful new therapeutic area for Apotex while strengthening our branded portfolio and expanding our presence in specialty care."
"We are delighted to expand our partnership with Apotex and further strengthen the global presence of the brand," says Jan Adams, Chief Commercial Officer (CCO) at Grünenthal. "Through this agreement, we are providing a valuable and well-established brand that can benefit people living with testosterone deficiency in Canada."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!